口服ESK-001高选择性变构抑制TYK2治疗中重度斑块状银屑病:STRIDE 12周随机双盲安慰剂对照剂量探索2期研究
STRIDE是一项2期双盲16周研究,中重度斑块状银屑病患者随机接受安慰剂或ESK-001(10mg每日一次至40mg每日两次)治疗12周。结果显示ESK-001呈剂量依赖性改善,最高剂量组PASI-75达64%而安慰剂组为0%(P<.0001),药物耐受良好,因不良事件停药率2.6%。
要点
- ESK-001在各剂量组均呈剂量依赖性疗效改善,最高剂量40mg每日两次效果最佳。
- 第12周时40mg每日两次组PASI-75达64%,安慰剂组为0%(P<.0001)。
- ESK-001耐受良好,无剂量限制性安全性发现,因不良事件停药率2.6%。
核心结论
- ESK-001在中重度斑块状银屑病患者中呈剂量依赖性显著改善症状与体征,最高剂量持续靶点抑制且耐受良好。
研究设计与样本
- STRIDE(NCT05600036,EudraCT 2022-002633-34)为2期双盲16周研究,患者随机分配至6个治疗组接受12周安慰剂或ESK-001(10mg每日一次至40mg每日两次)。
主要发现
- ESK-001在所有终点呈剂量依赖性改善,最高剂量组(40mg每日两次)疗效最大。
- 第12周时各ESK-001剂量组达到PASI-75的患者比例均高于安慰剂组:40mg每日两次组为64%,安慰剂组为0%(P<.0001)。
- ESK-001耐受良好,无剂量限制性安全性发现,因不良事件停药率为2.6%。
关键数值与推荐
- 第12周PASI-75:40mg每日两次组64% vs 安慰剂组0%(P<.0001)。
- 因不良事件停药率:ESK-001为2.6%。
临床怎么用
- ESK-001作为高选择性口服TYK2变构抑制剂,2期研究显示剂量依赖性疗效与良好耐受性,支持进一步开展后期临床研究。
局限性
- 每个治疗组样本量小,研究持续时间为16周。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: ESK-001, a novel allosteric, highly selective oral tyrosine kinase 2 inhibitor in development for treatment of immune-mediated disorders, was well-tolerated and achieved high levels of target inhibition in phase 1 studies with healthy volunteers. OBJECTIVE: To assess clinical efficacy, safety, and pharmacokinetics of ESK-001 compared to placebo in patients with moderate-to-severe plaque psoriasis. METHODS: STRIDE (NCT05600036, EudraCT Number 2022-002633-34) was a phase 2, double-blinded, 16-week study with patients randomized to 6 treatment groups for 12 weeks of placebo or ESK-001, ranging from 10 mg QD to 40 mg BID. RESULTS: ESK-001 demonstrated a dose-dependent improvement across all end points, with maximal efficacy observed in the highest dose arm (40 mg BID). At week 12, more patients achieved Psoriasis Area and Severity Index-75 in each ESK-001 dose arm compared to placebo: 64% in the 40 mg BID arm vs 0% with placebo (P < .0001). ESK-001 was well-tolerated, with no dose-limiting safety findings and a 2.6% rate of ESK-001 discontinuation due to adverse events. LIMITATIONS: Small sample size per treatment group and 16-week study duration. CONCLUSION: ESK-001 demonstrated significant dose-dependent improvement in signs and symptoms of psoriasis while achieving continuous target inhibition at the highest dose in patients with psoriasis and was well-tolerated.
引用
- Blauvelt A, Arenberger P, Sauder MB, et al. Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging phase 2 study. J Am Acad Dermatol. 2025. PMID: 40659116. doi:10.1016/j.jaad.2025.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。